Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopamine receptor (DAR) is required for the antibacterial immune responses in hemocytes of Procambarus clarkii.

Fish & shellfish immunology·2026
Same author

Translational landscape of cytokine-induced killer cell therapy: an analysis based on the Informa database.

Journal for immunotherapy of cancer·2026
Same author

Visible-Infrared Fusion Based on CNN and Deformable Transformer.

Journal of imaging·2026
Same author

Comparative Cochlear-Vestibular Aging Reveals Age-Aligned Mitochondrial Ultrastructural Burden, Mitophagy-Autophagy Remodeling, Synaptic Uncoupling, and Sensory Functional Decline.

Aging cell·2026
Same author

Epidemiological and genetic characteristics of a sapovirus GI.6 acute gastroenteritis outbreak in Jiangxi, China.

Scientific reports·2026
Same author

Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models.

BMC medical imaging·2026
Same journal

Retraction: Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression.

Oncotarget·2026
Same journal

TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.

Oncotarget·2026
Same journal

Retraction: MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.

Oncotarget·2026
Same journal

Laryngeal leiomyosarcoma: A rare case report and literature review.

Oncotarget·2026
Same journal

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone.

Oncotarget·2026
Same journal

DHHC3 interferes with antitumor immunity in melanoma cells.

Oncotarget·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Biomarker development in MET-targeted therapy.

Yanni Zhang1, Zhiqiang Du1, Mingqiang Zhang1

  • 1Amgen Biopharmaceutical Research and Development (Shanghai) Co., Ltd, Shanghai, China.

Oncotarget
|March 26, 2016
PubMed
Summary
This summary is machine-generated.

Accurate detection of MET receptor tyrosine kinase (RTK) signaling is crucial for identifying cancer patients who will benefit from MET-targeted therapies. Developing standardized biomarker assays is essential for effective clinical trial patient selection.

Keywords:
METMET-targeted therapyamplificationbiomarkeroverexpression

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K

Related Experiment Videos

Last Updated: Mar 23, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.5K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The MET receptor tyrosine kinase (RTK) pathway, activated by hepatocyte growth factor (HGF), plays a key role in cellular processes like proliferation, survival, and migration.
  • Aberrant MET/HGF signaling is frequently observed in human cancers, driving tumorigenesis and metastasis, making it a significant therapeutic target.
  • Clinical trials are evaluating selective HGF/MET inhibitors, but patient response prediction remains a challenge.

Purpose of the Study:

  • To review the critical role of HGF/MET signaling in cancer.
  • To highlight the need for accurate detection methods for MET signaling as a predictive biomarker.
  • To emphasize the importance of these biomarkers in guiding patient selection for MET-targeted therapies.

Main Methods:

  • Review of existing literature on MET/HGF signaling in cancer.
  • Analysis of current clinical trial strategies for MET-targeted therapies.
  • Discussion of the challenges in biomarker assessment for MET pathway activation.

Main Results:

  • MET/HGF signaling is a validated target in oncology due to its role in cancer progression.
  • Current methods for assessing MET levels and predicting response to MET inhibitors are not standardized.
  • Reliable biomarker detection is essential for optimizing patient stratification in clinical trials.

Conclusions:

  • Accurate and reliable detection of HGF/MET signaling is paramount for patient selection in clinical trials.
  • Standardized biomarker assays are needed to guide the clinical application of MET-targeted therapeutics.
  • Improved biomarker strategies will enhance the efficacy of precision medicine approaches in cancer treatment.